ICD-10 Code M11.2: Other Chondrocalcinosis (Pseudogout)

Key Takeaways

Pseudogout codes under M11.2 (Other chondrocalcinosis), not as a standalone indexed term

Anatomical site specificity required: M11.262 (left knee), M11.261 (right knee), M11.20 (unspecified site)

Clinical diagnosis of pseudogout maps to chondrocalcinosis codes in ICD-10-CM

Sixth character indicates laterality when documented-critical for complete code assignment

Common coding error: using unspecified site code when medical record documents specific joint

Introduction to Pseudogout ICD-10 Coding

Pseudogout-clinically known as calcium pyrophosphate deposition disease (CPPD)-presents a persistent coding challenge for rheumatology and orthopedic practices. The term “pseudogout” does not appear as an indexed entry in ICD-10-CM. Instead, coders must assign codes from the M11.2 category (Other chondrocalcinosis) to capture the diagnosis. This classification reflects the radiographic finding of calcium pyrophosphate crystals in cartilage, rather than the clinical syndrome itself.

The American Hospital Association’s Coding Clinic (Q3 2018) explicitly states that pseudogout is not an indexed term. Coders must reference the chondrocalcinosis parent code and select the appropriate sixth-character extension based on anatomical site and laterality. This guidance applies whether the encounter involves acute inflammatory episodes, chronic joint degeneration, or incidental radiographic findings discovered during imaging for other conditions.

Understanding the relationship between clinical terminology (pseudogout, CPPD) and ICD-10-CM classification (chondrocalcinosis) is essential for accurate claims management. Medical necessity depends on documentation linking the diagnosis to clinical presentation, imaging confirmation, or synovial fluid analysis showing positively birefringent rhomboid crystals. Without this documentation, payers may deny claims for treatments directed at CPPD.

Understanding M11.2: Other Chondrocalcinosis ICD-10 Code Structure

The M11.2 code category sits within the broader inflammatory arthropathies chapter (M00-M99) in ICD-10-CM. Category M11 specifically covers “Other crystal arthropathies,” distinguishing calcium pyrophosphate deposition from gout (M10) and other metabolic arthropathies. The “Other chondrocalcinosis” designation under M11.2 excludes codes for familial chondrocalcinosis (M11.1) and unspecified chondrocalcinosis without crystal identification (M11.9).

Code structure follows the standard ICD-10-CM hierarchy: category (M11), subcategory (M11.2), and character extensions indicating anatomical site. The CDC’s ICD-10-CM browser lists all valid combinations, but clinical documentation must support the specific site selected. A diagnosis of “chondrocalcinosis, knee” without laterality defaults to M11.269 (Other chondrocalcinosis, unspecified knee), sacrificing specificity that payers increasingly require for coverage determinations.

The Centers for Medicare & Medicaid Services (CMS) requires complete code assignment-selecting M11.2 alone without the site-specific extension results in claim rejection. CMS ICD-10 guidance specifies that codes lacking required characters return as “incomplete” in claims processing systems. This technical requirement means coders cannot bill M11.2 as a standalone code, even when documentation is vague about the affected joint.

Pseudogout ICD-10 Code M11.20: Other Chondrocalcinosis, Unspecified Site

M11.20 serves as the default assignment when clinical documentation confirms calcium pyrophosphate deposition but fails to specify which joint is affected. This scenario occurs most often in three contexts: initial emergency department presentations where imaging has not yet been performed, inpatient admissions documenting CPPD as a comorbidity without acute joint involvement, and outpatient encounters where the provider notes “history of pseudogout” without current active disease.

Using the unspecified site code carries reimbursement risk. Payers reviewing claims for joint aspiration (CPT 20610-20611), arthrocentesis, or intra-articular corticosteroid injection expect the diagnosis code to match the procedure’s anatomical site. A claim pairing CPT 20610 (arthrocentesis, major joint) with M11.20 may trigger a request for medical records, as the unspecified code suggests insufficient documentation to support a site-specific procedure. Practices managing rheumatology workflows should query providers whenever the medical record mentions a specific joint but the encounter form lists only “chondrocalcinosis.”

The code remains appropriate for reporting CPPD diagnosed via laboratory crystal analysis without accompanying joint symptoms. For example, a patient undergoing synovial fluid analysis for suspected gout whose results show calcium pyrophosphate crystals but no clinical arthritis would correctly map to M11.20 until follow-up imaging or examination identifies a specific joint with radiographic changes.

Pseudogout ICD-10 Code Selection by Anatomical Site

Site-specific code selection depends entirely on provider documentation. The medical record must state both the joint and, where applicable, the side (right/left). ICD-10-CM provides distinct codes for major joints-knee, ankle, wrist, hand, shoulder, hip-with laterality indicators built into the sixth character. The WHO’s coding conventions, adopted by CMS, require using the most specific code supported by the documentation. Selecting a less specific code when a more precise option exists violates coding guidelines and may constitute undercoding.

Knee involvement accounts for the majority of pseudogout cases. The M11.26 series covers this presentation with three variations: M11.261 (right knee), M11.262 (left knee), and M11.269 (unspecified knee). A progress note stating “acute chondrocalcinosis affecting the left knee with effusion” supports M11.262. The same clinical presentation described as “knee chondrocalcinosis” without laterality drops to M11.269, losing specificity that some commercial payers now tie to authorization requirements for imaging or therapeutic procedures.

Hand and wrist involvement follows similar logic but with subtle differences. M11.24 covers the hand series (M11.241 right, M11.242 left, M11.249 unspecified), while M11.23 addresses the wrist (M11.231 right, M11.232 left, M11.239 unspecified). Documentation specifying “chondrocalcinosis of the right second metacarpophalangeal joint” still codes to M11.241-ICD-10-CM does not distinguish individual hand bones or digits within the M11.24 series. If the provider documents involvement of both hands, assign two codes: M11.241 and M11.242. Bilateral involvement always requires two separate code assignments in ICD-10-CM.

Pseudogout ICD-10 Code M11.262: Other Chondrocalcinosis, Left Knee

M11.262 represents the most commonly assigned site-specific code for pseudogout, reflecting the condition’s predilection for weight-bearing joints. The code applies to any presentation where clinical or radiographic evidence confirms calcium pyrophosphate deposition in the left knee cartilage, regardless of whether the patient experiences acute inflammatory symptoms at the time of the encounter.

Three clinical scenarios justify M11.262 assignment. First, acute pseudogout attacks presenting with sudden-onset left knee pain, swelling, warmth, and reduced range of motion, confirmed by synovial fluid aspiration showing positively birefringent rhomboid crystals. Second, chronic chondrocalcinosis documented on left knee radiographs (linear calcifications in the meniscal cartilage) in patients with or without active symptoms. Third, incidental findings on imaging performed for other indications-such as MRI ordered to evaluate meniscal tears-that reveal chondrocalcinosis patterns requiring documentation as a secondary diagnosis.

Payer policies increasingly scrutinize site-laterality matching between diagnosis and procedure codes. A claim for left knee arthrocentesis (CPT 20610 with -LT modifier) paired with M11.269 (unspecified knee) may deny on the basis of code mismatch, even if the medical record clearly describes left-sided involvement. This administrative burden has pushed many musculoskeletal practices toward template-based documentation that automatically captures laterality during the examination.

Pseudogout ICD-10 Code M11.261: Other Chondrocalcinosis, Right Knee

M11.261 mirrors M11.262 in clinical application, differentiated only by right-sided involvement. The code’s selection follows identical documentation requirements: the medical record must explicitly state “right knee” or use anatomical descriptors that unambiguously indicate the right side. Abbreviations like “R knee” or “rt knee” suffice, but phrases like “dominant knee” or “affected knee” without further clarification do not meet specificity thresholds unless the chart elsewhere documents which knee is dominant or affected.

Bilateral presentations create a coding decision point. If both knees show radiographic chondrocalcinosis but only the right knee is symptomatic during the encounter, coders assign M11.261 as the primary diagnosis and M11.262 as a secondary diagnosis to capture the left knee’s chronic condition. Some practices reverse this order, listing the symptomatic knee first regardless of laterality. Either approach is defensible under ICD-10-CM guidelines, but consistency within a practice reduces claim variation and simplifies payer audits.

The distinction between acute inflammatory episodes and chronic radiographic findings matters for treatment planning but not for code selection-both scenarios use M11.261 when the right knee is involved. However, documentation should differentiate these presentations to support medical necessity for different interventions. Acute pseudogout attacks justify arthrocentesis, corticosteroid injection, or short-term NSAID therapy. Chronic asymptomatic chondrocalcinosis typically does not support procedural billing unless the patient develops complications requiring intervention.

ICD-10-CM Codes for Pseudogout by Joint Location

This table captures the complete M11.2 code set available in the 2026 ICD-10-CM code file. Note that M11.29 (multiple sites) serves as the appropriate code when documentation describes polyarticular disease affecting three or more joints simultaneously. Assign this code rather than listing multiple individual site codes, which artificially inflates claim complexity and may trigger payer edits.

Documentation Requirements for Pseudogout ICD-10 Coding

Complete documentation for pseudogout must establish three elements: clinical presentation, anatomical location with laterality, and diagnostic confirmation. Each element ties directly to code selection and medical necessity justification. Incomplete documentation forces coders toward less specific codes, undermining reimbursement and creating audit risk.

Clinical presentation documentation describes the patient’s symptoms and physical examination findings. For acute pseudogout attacks, this includes onset pattern (sudden vs gradual), pain severity, joint swelling measurements, erythema presence, warmth on palpation, and range-of-motion limitations. Chronic presentations require documentation of joint stiffness, functional impairment, and any deformity or crepitus noted during examination. The provider’s assessment should explicitly link these findings to chondrocalcinosis rather than other differential diagnoses like gout, septic arthritis, or osteoarthritis.

Anatomical documentation must specify both the affected joint and its side. Acceptable formats include full descriptions (“left knee”), standard abbreviations (“L knee”), or anatomical modifiers (“LT knee”). Unacceptable formats include vague references (“knee pain”), sidedness inferred from context without explicit statement, or references to “the affected joint” without prior documentation establishing which joint is affected. Many clinical documentation tools now auto-populate laterality fields when providers click anatomical diagrams, reducing omission errors that lead to unspecified site code assignments.

Diagnostic confirmation comes from three possible sources: synovial fluid analysis, radiographic imaging, or clinical diagnosis based on presentation patterns. Synovial fluid showing weakly positive birefringent rhomboid crystals under polarised light microscopy provides definitive confirmation. Radiographic chondrocalcinosis-linear calcifications in cartilage visible on plain X-rays or CT scans-offers supportive evidence but does not always correlate with symptomatic disease. Clinical diagnosis without confirmatory testing remains acceptable when the presentation is classic and other causes have been reasonably excluded, but documentation must explain why definitive testing was not performed.

Common Documentation Pitfalls

Three documentation patterns consistently create coding problems. First, using the term “pseudogout” without mentioning chondrocalcinosis or CPPD anywhere in the note. While clinically synonymous, the absence of ICD-10-CM’s indexed terminology makes code assignment ambiguous and may prompt coding queries that delay claim submission. Second, documenting bilateral involvement but only coding one side. When both knees show chondrocalcinosis, assign both M11.261 and M11.262-using only M11.29 (multiple sites) would be incorrect unless three or more joints are affected.

Third, describing radiographic findings without tying them to clinical significance. An X-ray report noting “incidental chondrocalcinosis in the left knee meniscus” does not automatically support a diagnosis code assignment if the patient’s visit addressed an unrelated complaint and the provider did not assess or discuss the finding. ICD-10-CM codes must reflect conditions that influence the encounter-either actively treated, evaluated, or monitored. Incidental findings require mention in the provider’s assessment or plan to justify code assignment.

Relationship Between Chondrocalcinosis and Pseudogout Terminology

The disconnect between clinical language (pseudogout) and coding taxonomy (chondrocalcinosis) stems from ICD-10-CM’s structure, which organises conditions by pathological mechanism rather than clinical syndrome names. Chondrocalcinosis describes the radiographic or microscopic finding of calcium pyrophosphate crystals deposited in cartilage. Pseudogout refers to the acute inflammatory arthritis syndrome that sometimes occurs when these crystals are released into the joint space, triggering an immune response mimicking gout attacks.

Not all patients with chondrocalcinosis experience pseudogout attacks. Many individuals show radiographic calcifications on X-rays performed for other reasons yet never develop joint inflammation. These asymptomatic cases still code to M11.2 series when documented as a diagnosis-the crystals’ presence constitutes a pathological state warranting code assignment, even without clinical symptoms. Conversely, patients presenting with acute inflammatory monoarthritis suspicious for pseudogout may require coding before confirmatory testing, using M11.2 series codes with documentation noting presumptive diagnosis pending synovial fluid analysis.

The term “calcium pyrophosphate deposition disease” (CPPD) encompasses the full spectrum from asymptomatic radiographic findings through acute inflammatory attacks to chronic arthropathy. ICD-10-CM does not distinguish between these presentations within the M11.2 series-all variants code identically based solely on anatomical site. Differentiation occurs through supplementary codes for associated conditions (such as M25.5 for joint effusion) or through procedure codes documenting the interventions performed. This flat coding structure simplifies code selection but requires detailed documentation elsewhere in the medical record to capture disease severity and treatment complexity.

Clinical practices managing CPPD across its spectrum benefit from standardised documentation templates that capture all required elements. Specialty-specific EHR templates for rheumatology encounters should include discrete fields for affected joints with laterality checkboxes, dropdown menus for crystal identification results, and auto-populated text blocks describing typical acute vs chronic presentations. This structure ensures coders receive complete information without relying on unstructured narrative notes that may omit key details.

Automate ICD-10-CM Code Selection in Your Rheumatology Workflows

Pabau's clinical documentation platform links diagnosis codes directly to anatomical site selection during the exam, ensuring complete code assignment without manual lookup. Template-based charting captures laterality, crystal analysis results, and joint-specific findings in structured fields that auto-populate billing data.

Book a demo

Coding Pseudogout with Associated Conditions

Pseudogout rarely occurs in isolation. Patients typically present with comorbid conditions that either predispose to CPPD or complicate its clinical presentation. Code assignment must capture both the chondrocalcinosis and any associated diagnoses that influence treatment decisions or medical necessity. The order of code listing follows ICD-10-CM sequencing guidelines: code the condition actively treated during the encounter first, followed by comorbidities in order of clinical significance.

Acute inflammatory episodes often present with joint effusion requiring aspiration. When arthrocentesis is performed, assign both the M11.2 code for the underlying chondrocalcinosis and M25.46 series for joint effusion (M25.461 right knee, M25.462 left knee, etc.). This dual coding supports medical necessity for the procedure while documenting the acute complication. If the aspiration reveals infection alongside CPPD crystals, sequence the septic arthritis code (M00 series) before M11.2, as the bacterial infection represents the more urgent condition requiring immediate treatment.

Metabolic conditions associated with CPPD include hyperparathyroidism (E21 series), hemochromatosis (E83.110), hypophosphatasia (E83.30), and hypomagnesemia (E83.42). When these conditions coexist, code both diagnoses if documentation shows active management of each. For example, a patient seen for pseudogout management whose medical record also notes ongoing treatment for hyperparathyroidism would receive both M11.262 (if left knee is affected) and the appropriate E21 code. However, historical diagnoses no longer requiring treatment should not be coded during encounters focused solely on acute arthritis management.

Osteoarthritis frequently develops in joints affected by chronic chondrocalcinosis. ICD-10-CM allows coding both conditions when documentation supports dual diagnosis. A patient with chronic M11.262 (left knee chondrocalcinosis) who develops progressive joint space narrowing and osteophyte formation documented on X-rays may also receive M17.12 (unilateral primary osteoarthritis, left knee). This combined coding accurately reflects disease burden and justifies more intensive interventions like prescription management for chronic pain or consideration of joint replacement surgery.

Sequencing Rules for Multiple Joint Involvement

Polyarticular presentations create sequencing decisions when multiple joints are simultaneously affected. If three or more joints show active chondrocalcinosis during the encounter, M11.29 (multiple sites) may be the most appropriate code rather than listing each joint individually. However, when a patient has chronic involvement of multiple joints but presents with acute inflammation in only one joint, sequence that joint’s specific code first (e.g., M11.262 for acute left knee pseudogout) followed by M11.29 to capture the chronic polyarticular disease.

Bilateral involvement of the same joint type requires two separate code assignments. A patient with chondrocalcinosis affecting both knees receives both M11.261 and M11.262, not M11.29, because M11.29 is reserved for cases involving different joint types (knee plus wrist, shoulder plus ankle, etc.). If only one knee is symptomatic during the encounter but both show radiographic changes, sequence the symptomatic side first. This approach aligns with ICD-10-CM’s principle of prioritising conditions actively managed during the encounter.

Common Coding Errors and How to Avoid Them

The most frequent pseudogout coding error is selecting M11.20 (unspecified site) when the medical record contains site-specific information. This typically occurs when coders work from encounter forms or problem lists that list only “chondrocalcinosis” as the diagnosis, failing to reference the body of the clinical note where the provider documents joint examination findings. Audit your coding workflow to ensure coders review both structured data fields and narrative notes before assigning codes. If your practice shows a pattern of high M11.20 usage relative to site-specific codes, implement a coding query protocol requiring review of the full progress note whenever the encounter form lacks laterality information.

The second common error is miscoding pseudogout as gout (M10 series). While the conditions share similar acute presentations, the crystal types differ-gout involves monosodium urate crystals (negatively birefringent needle-shaped), while pseudogout involves calcium pyrophosphate (weakly positive birefringent rhomboid). Documentation must clearly identify which crystal type was found on synovial fluid analysis. If the provider uses the term “pseudogout” without specifying crystal type, query for clarification before assigning an M10 code. Never assume crystal type based solely on clinical presentation, as the two conditions can mimic each other closely.

Third, practices sometimes fail to update diagnosis codes when patients transition from acute to chronic phases. A patient initially coded with M11.262 during an acute inflammatory episode may continue receiving that code at follow-up visits months later when symptoms have resolved but radiographic changes persist. While the code itself remains appropriate, documentation should reflect the current clinical status-whether the patient is experiencing active inflammation, chronic pain, functional limitations, or asymptomatic radiographic findings. This distinction affects medical necessity justification for ongoing treatment and helps payers understand why continued care is warranted.

Fourth, incorrect use of M11.29 (multiple sites) occurs when coders misinterpret bilateral involvement of a single joint type as polyarticular disease. M11.29 is appropriate only when chondrocalcinosis affects three or more joints or two or more different joint types (e.g., knee and wrist). Bilateral knee involvement requires M11.261 and M11.262, not M11.29. Review your practice’s M11.29 usage patterns-if this code appears frequently in claims for patients with only bilateral knee or hand involvement, retraining may be needed on the distinction between bilateral and polyarticular presentations.

ICD-10-CM Updates and Future Coding Changes

The M11.2 code series has remained stable through recent ICD-10-CM annual updates, with no new codes added or deleted since 2016 implementation. This stability reflects the well-established clinical understanding of CPPD and the adequacy of the existing code structure to capture disease variations through site-specific assignments. However, coders must stay current with annual updates, as even minor changes to code definitions or usage notes can affect claim processing.

The 2026 ICD-10-CM code file maintains all existing M11.2 codes without modification. The American Hospital Association’s Coding Clinic has published limited guidance specific to pseudogout coding, with the most relevant advisory appearing in Q3 2018 clarifying that “pseudogout” is not an indexed term and must be coded to Other chondrocalcinosis (M11.2). No subsequent Coding Clinic articles have amended or superseded this guidance, making it the authoritative reference for ambiguous cases.

Future coding changes may emerge from two sources. First, ongoing research into CPPD subtypes-particularly distinctions between sporadic, familial, and metabolic forms-could prompt ICD-11 to introduce more granular classification schemes. The WHO’s ICD-11 browser shows preliminary structures for crystal arthropathies that separate CPPD into distinct entities based on clinical presentation patterns. If these changes are adopted in future ICD-CM versions, practices will need updated documentation templates and coder training to support the new classification logic.

Second, advances in diagnostic imaging-particularly dual-energy CT scanning that can identify calcium pyrophosphate deposits non-invasively-may influence documentation requirements. As this technology becomes more widely available, payers might begin requiring imaging confirmation before authorising certain treatments, parallel to how they currently handle gout management with dual-energy CT. Practices should monitor payer policy updates and adjust documentation protocols accordingly, ensuring that diagnostic method (clinical diagnosis, radiographic finding, or synovial fluid analysis) is clearly stated in encounter notes.

Staying current with coding changes requires regular review of CMS update files, subscription to AHA Coding Clinic, and participation in professional coding organisations like AAPC or AHIMA. Many practice management systems include automated code update modules that flag outdated codes and prompt review of documentation patterns affected by annual changes. Implementing these tools reduces the administrative burden of manual code file monitoring while ensuring claims remain compliant with current coding guidelines.

Expert Picks

Need guidance on ICD-10-CM coding for other rheumatological conditions? Intraparenchymal Hemorrhage ICD-10 Codes demonstrates similar site-specificity requirements for neurological coding.

Managing chronic arthritis documentation workflows? Physical Therapy EMR explores specialty-specific EHR features for musculoskeletal practices.

Looking for structured clinical documentation tools? Echo AI provides AI-powered clinical note generation that auto-populates diagnosis codes from provider dictation.

Conclusion: Mastering Pseudogout ICD-10 Coding

Accurate pseudogout coding hinges on understanding the relationship between clinical terminology and ICD-10-CM taxonomy. While providers diagnose “pseudogout” or “CPPD,” coders must translate these terms into the M11.2 (Other chondrocalcinosis) code series, selecting the most specific site and laterality combination supported by documentation. This translation requires both coding knowledge and careful review of clinical notes to extract the anatomical detail needed for complete code assignment.

The most critical success factor is complete documentation at the point of care. Providers must document not just the diagnosis but the affected joint, its laterality, and the basis for the diagnosis (clinical presentation, imaging findings, or synovial fluid analysis). When this documentation is thorough, coding becomes straightforward. When it is incomplete, coders face difficult decisions between querying providers-which delays claims-and selecting less specific codes that may reduce reimbursement or trigger audits.

Implementing structured documentation templates, training providers on ICD-10-CM’s site-specificity requirements, and conducting regular coding audits will minimise errors and optimise reimbursement for pseudogout management. As crystal arthropathies continue to increase in prevalence with population aging, mastering these coding principles becomes essential for any practice managing musculoskeletal conditions.

Frequently Asked Questions